An Institute of Medicine report released Tuesday blamed poor communication between clinicians for many diagnostic errors and called for new reimbursement models to improve coordination and optimize the testing that patients receive.
Under the crosswalk system, claims that are submitted using ICD-10 codes will be cross-referenced to identify the appropriate ICD-9 codes that will be used to process the claims.
California is one of four states that received a federal waiver to use a "crosswalk" coding translation system for Medi-Cal claims for the Oct. 1 transition to ICD-10 coding.
The state Department of Health Care Services (DHCS) said it was granted a waiver from the Centers for Medicare & Medicaid Services (CMS) to use the crosswalk for ICD-9 codes until it replaces an antiquated health information technology system. Other states that received similar waivers are Louisiana, Maryland, and Montana.
DHCS officials said the department requested the waiver as a temporary fix while it works with Xerox Health Systems to create a new health information system for Medi-Cal. "California is working on a computer system replacement that, when implemented, will process claims using ICD-10," said Adam Weintraub, assistant deputy director for DHCS. "Medi-Cal requested and received approval from CMS to implement ICD-10 on our legacy system using a crosswalk. This is designed to reduce the cost and avoid changes to an aging system that is already being replaced."
Under the crosswalk system, claims that are submitted using the new ICD- 10 codes will be cross-referenced to identify the appropriate ICD-9 codes that will be used to process the claim. DHCS said the crosswalk will be used until the project to replace the state's existing computer system is completed in 2017. DHCS said its new system "has mapped all ICD-10 codes to corresponding ICD-9 codes starting with General Equivalency Mapping and Reimbursement Mappings provided by CMS."
And though DHCS is using the crosswalk for Medi-Cal, Weintraub said that "DHCS is fully prepared to implement ICD-10" and will "accept provider claims with ICD-10 codes, correctly adjudicate those claims, and return ICD-10 codes to providers."
Weintraub said the state "has thoroughly tested the crosswalk system in order to minimize gaps or variances in payments and to reduce any potential of disruption or impact to quality of care as a result of the ICD-10 implementation." He added that the crosswalk "is solely used internally within the California Medicaid Management Information System" and that "CMS staff has joined our state staff to train providers on their own readiness for ICD-10."
The California Hospital Association (CHA) said it has some concerns about the crosswalk system being implemented during an ICD-10 transition period that already carries the potential for billing issues and other problems.
"As is the case with any new system, the introduction of ICD-10 will create a greater margin for error in billing and payments," said Amber Ott, vice president of finance for the CHA. "Our concern with the crosswalk program is that it will add to that margin for error." Ott also said that hospitals in California lose billions of dollars each year with Medi-Cal because of low reimbursement rates and that "any additional problems with ICD-10 will just add to those losses."
The California Medical Association (CMA) did not offer an opinion on the crosswalk program but CMA associate vice president of public affairs Molly Weedn said the organization will "watch the situation closely and make sure our members are aware of what's going on." Weedn said the CMA has been assisting members with the ICD-10 transition through online toolkits, webinars, and other educational programs and materials.
Five years after the Affordable Care Act helped set off a health-care merger frenzy, the pace of consolidation is accelerating, transforming the medical marketplace into a land of giants. The trend is under a new spotlight now, as Congress zeroes in on the competitive and cost impact of proposed deals that would collapse the health-insurance industry's top five players into just three massive companies, each with more than $100 billion in annual revenue. On Tuesday, a Senate subcommittee is set to hear testimony from the chief executives of Aetna Inc., which plans to acquire Humana Inc., and Anthem Inc., which is seeking to buy Cigna Corp. , as well as the head of the American Hospital Association. [Subscription Required]
Nonprofit hospital bonds are being issued at the fastest pace since at least 2012 as earlier concerns over the Affordable Care Act's implementation have largely abated. As of Sept. 16, nonprofit hospitals in the U.S. have issued $18 billion of municipal bonds this year, already surpassing 2013's and 2014's annual totals, according to Bloomberg data. This year's pick-up in issuance reverses two years of pullback. As the Affordable Care Act — often dubbed Obamacare — began official implantation in 2013, wary hospitals put the brakes on capital investment until the future was more clear, said Mike Quinn, a managing director at Chicago-based B.C. Ziegler & Co.
Florida-based healthcare system Adventist Health System has agreed to pay $118.7 million to settle a whistleblower lawsuit that accused it of paying kickbacks to doctors in exchange for referrals, attorneys for the plaintiffs announced on Monday. The agreement comes in a lawsuit filed by three former employees of Adventist's Park Ridge Health hospital in Hendersonville, North Carolina, in 2012. It also resolves claims in a separate 2013 lawsuit containing similar accusations. The bulk of the settlement, $115 million, will go to the federal government, with $3.4 million going to the state of Florida and the rest divided among North Carolina, Tennessee and Texas, according Peter Chatfield, a lawyer for the plaintiffs.
A huge overnight price increase for an important tuberculosis drug has been rescinded after the company that acquired the drug gave it back to its previous owner under pressure, it was announced on Monday. However, outrage over a gigantic price increase for another drug spread into the political sphere on Monday, causing biotechnology stocks to fall broadly as investors worried about possible government action to control pharmaceutical prices. The Nasdaq Biotechnology Index fell more than 4 percent. "Price-gouging like this in the specialty drug market is outrageous," Hillary Rodham Clinton, a contender for the Democratic presidential nomination, said in a tweet on Monday.